Evidence map›Paper›PMID 33536042›Full record

ArticleHealth and quality of life outcomes2021

Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19.

Felipe V C Machado, Roy Meys, Jeannet M Delbressine, Anouk W Vaes, Yvonne M J Goërtz, Maarten van Herck, Sarah Houben-Wilke, Gudula J A M Boon, Stefano Barco, Chris Burtin and 11 more

Open access · goldAbstract read
In one paragraph

Article in Health and quality of life outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
17.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Bridging Gaps in Long COVID Therapy: A Review.Current medicinal chemistry · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Ashwagandha (BMJ open · 2025
    Article
  17. Article
  18. Article
  19. Development and validation of an instrument for tracking and analyzing recovery from symptoms associated with COVID-19.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025
    Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 5 countries.

Felipe V C MachadoDepartment of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands. felipemachado@ciro-horn.nl.ORCID http://orcid.org/0000-0003-1910-7695
Roy MeysDepartment of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
Jeannet M DelbressineDepartment of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
Anouk W VaesDepartment of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
Yvonne M J GoërtzDepartment of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
Maarten van HerckDepartment of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
Sarah Houben-WilkeDepartment of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
Gudula J A M BoonDepartment of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
Stefano BarcoCenter for Thrombosis and Haemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Chris BurtinREVAL Rehabilitation Research Center, BIOMED Biomedical Research Institute, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium.
Alex van 't HulDepartment of Respiratory Diseases, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Rein PosthumaDepartment of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
Frits M E FranssenDepartment of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
Yvonne SpiesLung Foundation Netherlands, Amersfoort, The Netherlands.
Herman VijlbriefLung Foundation Netherlands, Amersfoort, The Netherlands.
Fabio PittaLaboratory of Research in Respiratory Physiotherapy (LFIP), Department of Physiotherapy, State University of Londrina (UEL), Londrina, Brazil.
Spencer A RezekInstitute of Therapies and Rehabilitation, Kantonsspital Winterthur, Winterthur, Switzerland.
Daisy J A JanssenDepartment of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
Bob SiegerinkCenter for Stroke Research Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
Frederikus A KlokDepartment of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
Martijn A SpruitDepartment of Research and Development, CIRO+, PO Box 4080, 6080 AB, Horn, Haelen, The Netherlands.
Maastricht University · NLCiro · NLJohannes Gutenberg University Mainz · DELeiden University Medical Center · NLLung Foundation Netherlands · NLUniversidade Estadual de Londrina · BRHasselt University · BEKantonsspital Winterthur · CHRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn increasing number of subjects are recovering from COVID-19, raising the need for tools to adequately assess the course of the disease and its impact on functional status. We aimed to assess the construct validity of the Post-COVID-19 Functional Status (PCFS) Scale among adult subjects with confirmed and presumed COVID-19.

methodsAdult subjects with confirmed and presumed COVID-19, who were members of an online panel and two Facebook groups for subjects with COVID-19 with persistent symptoms, completed an online survey after the onset of infection-related symptoms. The number and intensity of symptoms were evaluated with the Utrecht Symptom Diary, health-related quality of life (HrQoL) with the 5-level EQ-5D questionnaire, impairment in work and activities with the Work Productivity and Activity Impairment questionnaire and functional status with the PCFS Scale.

results1939 subjects were included in the analyses (85% women, 95% non-hospitalized during infection) about 3 months after the onset of infection-related symptoms. Subjects classified as experiencing 'slight', 'moderate' and 'severe' functional limitations presented a gradual increase in the number/intensity of symptoms, reduction of HrQoL and impairment in work and usual activities. No differences were found regarding the number and intensity of symptoms, HrQoL and impairment in work and usual activities between subjects classified as experiencing 'negligible' and 'no' functional limitations. We found weak-to-strong statistical associations between functional status and all domains of HrQoL (r: 0.233-0.661). Notably, the strongest association found was with the 'usual activities' domain of the 5-level EQ-5D questionnaire.

conclusionWe demonstrated the construct validity of the PCFS Scale in highly-symptomatic adult subjects with confirmed and presumed COVID-19, 3 months after the onset of symptoms.

Indexed as

ConvalescenceFunctional StatusQuality of LifeAdultBelgiumCOVID-19Cross-Sectional StudiesFemaleHumansMaleMiddle AgedNetherlandsReproducibility of ResultsSARS-CoV-2Surveys and QuestionnairesFunctional statusQuality of lifeSARS-CoV-2Symptoms

Identifiers

PMID33536042
PMCPMC7856622
OpenAlexW3126517207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.